Investment Pitches

Pitch Summary:
Investors cheered a solid fiscal year Q3 performance from Salesforce, with results driven by strength in subscription revenues, current remaining performance obligations (CRPO), and operating margin. Both the Sales and Service Clouds returned to double-digit growth, fueled by strong adoption of multi-cloud and vertical-specific solutions. These results highlight Salesforce's ability to address diverse customer needs and sustain growth across its core offerings. Management expressed significant excitement about Agentforce, an organically developed generative AI product that is garnering enthusiasm from both system integrator partners and customers alike. This innovation underscores Salesforce's commitment to delivering innovative solutions that enhance customer engagement and drive productivity. While Agentforce's contributions to subscription revenues and CRPO bookings are still immaterial for now, the growing pipeline provides a solid foundation for optimism around Salesforce's ability to productize and monetize its generative AI offerings.

BSD Analysis:
Mar Vista expresses bullish sentiment on Salesforce following strong Q3 results that demonstrated the company's ability to return to double-digit growth across core Sales and Service Cloud offerings. The manager highlights robust subscription revenue growth and improved operating margins as key performance indicators. The introduction of Agentforce, Salesforce's organically developed generative AI product, represents a significant catalyst for future growth despite currently immaterial revenue contributions. Strong adoption of multi-cloud and vertical-specific solutions demonstrates the platform's versatility and market penetration capabilities. The growing Agentforce pipeline provides visibility into future AI-driven revenue streams, positioning Salesforce to capitalize on the generative AI trend. Management's excitement and positive customer reception suggest strong product-market fit for the AI offerings. Mar Vista views Salesforce's innovation in AI and sustained growth across core products as evidence of the company's competitive positioning in the evolving CRM landscape.

Pitch Summary:
Broadcom reported a strong fiscal year Q4 2024, exceeding expectations and reinforcing its leadership in custom AI accelerator solutions. Investors reacted positively to the company's robust performance and outlook, particularly for its AI semiconductor-related revenues and its long-term growth potential. The outlook for continued demand for Broadcom's custom AI accelerator products surprised many who expected a slowdown ahead of its new product, which is set to ramp in the second half of fiscal year 2025. The announcement of a long-term service addressable market (SAM) of $60-to-$90 billion further highlighted Broadcom's significant growth runway and market opportunity in the custom AI accelerator market. Broadcom's software business continues to deliver stable results, with the VMware acquisition integration performing ahead of plan. The stability in software business, coupled with Broadcom's strong execution and promising outlook in high-growth areas like AI semiconductors, should position the company for continued shareholder value creation.

BSD Analysis:
Mar Vista maintains a bullish stance on Broadcom, highlighting the company's dominant position in custom AI accelerator solutions and strong Q4 2024 performance that exceeded expectations. The manager emphasizes Broadcom's significant growth runway with a $60-90 billion long-term service addressable market in AI accelerators, positioning the company to capitalize on the AI semiconductor boom. The successful VMware acquisition integration demonstrates management's execution capabilities while providing stable software revenue streams. With new AI accelerator products ramping in H2 2025 and continued demand surprising skeptics, Broadcom appears well-positioned for sustained growth. The combination of AI semiconductor leadership and stable software operations creates a compelling investment thesis. Mar Vista views the company's strong execution track record and promising outlook in high-growth AI markets as key drivers for continued shareholder value creation. The pitch reflects confidence in Broadcom's ability to maintain its competitive advantages in the rapidly expanding AI infrastructure market.

Pitch Summary:
Microchip Technology (MCHP) has historically been one of the best-executing semiconductor companies in the industry. However, in this recent cycle, the company uncharacteristically faced execution challenges that have led to a deep, inventory-driven downturn. This downcycle is proving to be longer and more pronounced than initially predicted, and MCHP's recovery has been slower compared to its peers. To address these challenges, the Board has reinstated Steve Sanghi as CEO to help steer the business back on track. While we view this leadership change as a positive step, we believe the extended nature of this downturn will require more time to resolve than originally expected. Given these factors, we have decided to divest our position in MCHP.

BSD Analysis:
Mar Vista turned bearish on Microchip Technology despite the company's historically strong execution track record in semiconductors. The manager highlights uncharacteristic execution challenges leading to a deep, inventory-driven downturn that has proven longer and more severe than initially anticipated. MCHP's recovery has lagged semiconductor peers, indicating company-specific rather than industry-wide issues. While the board's decision to reinstate Steve Sanghi as CEO is viewed positively, Mar Vista believes the extended downturn duration will require more time to resolve than originally expected. The investment thesis deteriorated due to the combination of execution missteps, prolonged inventory correction, and slower recovery pace relative to competitors. Despite acknowledging MCHP's historical excellence, the manager concluded that the current cycle challenges and extended recovery timeline warranted a complete exit from the position.

Pitch Summary:
Our investment in GXO Logistics was under review after growth and market share gains did not meet our expectations from Q4 2023 to Q2 2024. During this period, management announced a potential sale of the business, which caused the shares to appreciate by over 15%. We seized this opportunity to reduce the weighting of the investment closer to our estimate of fair value. However, once the CEO announced his retirement and the company ended the potential sale, we exited our small remaining position.

BSD Analysis:
Mar Vista developed a bearish view on GXO Logistics due to disappointing operational performance and strategic uncertainty. The manager placed the investment under review after growth and market share gains failed to meet expectations from Q4 2023 to Q2 2024, indicating fundamental execution challenges. When management announced a potential sale, shares appreciated over 15%, providing an opportunity to reduce position size closer to fair value estimates. However, the investment thesis further deteriorated when the CEO announced retirement and the company abandoned sale discussions, creating leadership uncertainty and strategic direction concerns. The combination of underperforming growth metrics, unmet market share expectations, and management instability led to a complete exit. Mar Vista's decision reflects concerns about GXO's ability to execute its logistics strategy and capture expected market opportunities in the competitive supply chain services sector.

Pitch Summary:
Over the past year, our investment in Disney unfolded as expected. With one of the most compelling combinations of global content and consumer brands, Disney's media business has finally reached a positive turning point. The company is successfully adapting its operations to address the ongoing transformation of the media industry. This progress has been reflected in its stock performance, closing the gap to its intrinsic value. As friction costs diminish within the media ecosystem, companies with global audiences are receiving help from their unmatched scale advantages. While Disney is setting up itself as a long-term leader in the digital streaming space, the landscape of content distribution is still in flux. Platform giants like Netflix, Alphabet, Amazon, and Apple are rapidly dismantling competitive barriers, further intensifying the pace of change. This secular disruption places Disney and other traditional media companies in a precarious position. With the risk-reward profile for Disney no longer favoring significant upside, we exited our investment during the quarter.

BSD Analysis:
Mar Vista adopted a neutral stance on Disney, ultimately exiting the position after achieving expected returns. The manager acknowledges Disney's successful adaptation to media industry transformation, with the media business reaching a positive inflection point and stock performance closing the valuation gap. Disney's compelling combination of global content and consumer brands, along with scale advantages in the streaming ecosystem, positioned it as a potential long-term digital leader. However, the investment thesis deteriorated due to intensifying competitive pressures from platform giants including Netflix, Alphabet, Amazon, and Apple, which are dismantling traditional competitive barriers. The manager views the content distribution landscape as increasingly volatile, placing traditional media companies like Disney in a precarious position. With the risk-reward profile no longer favoring significant upside potential, Mar Vista concluded that Disney had reached fair value and exited the position, reflecting a neutral outlook on future prospects.

Pitch Summary:
Healthcare stocks in general, and Life Science tool businesses more specifically, ended 2024 on a downbeat as investor sentiment is still cautious on the market's post-Covid recovery. Hopes for an above-average industry growth rebound in 2025 were muted by managements' more cautious guidance. Investor concerns over the Trump administration's healthcare leadership and policies further dampened optimism for a strong 2025. Tariff impacts, NIH funding and Biotech/pharma spending top the list of investor concerns. We believe Mettler-Toledo's and Danaher's secular growth opportunities stay intact. Both businesses compete in key, defensible segments of the industry's value chain and have strong pricing power and margin expansion opportunities. Long-term secular drivers for scientific research and commercialization of biologic therapeutics and molecular diagnostic should drive above-average growth for both businesses.

BSD Analysis:
Mar Vista maintains a bullish perspective on Danaher despite sector-wide challenges affecting life sciences tools companies in 2024. The manager acknowledges near-term headwinds including cautious management guidance, post-COVID recovery uncertainty, and Trump administration policy concerns around tariffs, NIH funding, and biotech spending. However, the investment thesis centers on Danaher's defensible competitive position in critical industry value chain segments with strong pricing power and margin expansion capabilities. The manager emphasizes that long-term secular growth drivers remain intact, particularly expansion in scientific research and commercialization of biologic therapeutics and molecular diagnostics. Mar Vista views current weakness as sentiment-driven rather than fundamental, believing Danaher's market position in essential life sciences infrastructure will drive above-average growth as industry conditions normalize. The company's diversified portfolio across life sciences, diagnostics, and environmental solutions provides multiple growth avenues.

Pitch Summary:
Healthcare stocks in general, and Life Science tool businesses more specifically, ended 2024 on a downbeat as investor sentiment is still cautious on the market's post-Covid recovery. Hopes for an above-average industry growth rebound in 2025 were muted by managements' more cautious guidance. Investor concerns over the Trump administration's healthcare leadership and policies further dampened optimism for a strong 2025. Tariff impacts, NIH funding and Biotech/pharma spending top the list of investor concerns. We believe Mettler-Toledo's and Danaher's secular growth opportunities stay intact. Both businesses compete in key, defensible segments of the industry's value chain and have strong pricing power and margin expansion opportunities. Long-term secular drivers for scientific research and commercialization of biologic therapeutics and molecular diagnostic should drive above-average growth for both businesses.

BSD Analysis:
Mar Vista maintains a bullish long-term view on Mettler-Toledo despite near-term sector headwinds and cautious 2025 guidance. The manager acknowledges broad healthcare and life sciences tools sector weakness, attributed to post-COVID recovery uncertainty and Trump administration policy concerns including tariffs, NIH funding, and biotech spending. However, the investment thesis rests on Mettler-Toledo's defensible market position in key industry value chain segments with strong pricing power and margin expansion potential. The manager emphasizes that secular growth drivers remain intact, particularly scientific research expansion and commercialization of biologic therapeutics and molecular diagnostics. Mar Vista views current weakness as temporary sentiment-driven rather than fundamental deterioration. The company's competitive positioning in essential life sciences instrumentation should drive above-average growth as industry conditions normalize and long-term research spending trends resume.

Pitch Summary:
After appreciating by almost 40% during the prior two quarters, American Tower's stock declined 21% in the fourth quarter as expectations for more aggressive Federal Reserve interest cuts moderated and longer-term interest rates rose. The fundamental outlook for American Tower did not change materially during the period, with management providing guidance that was in line with consensus expectations. The long-term global opportunities for 5G deployment, edge-of-network computing and datacenters are still attractive and are not fully reflected in the current stock price, in our opinion.

BSD Analysis:
Mar Vista maintains a bullish view on American Tower despite Q4 underperformance, attributing the 21% decline to interest rate dynamics rather than fundamental deterioration. The manager emphasizes that the company's fundamental outlook remained unchanged, with management guidance meeting consensus expectations. The investment thesis centers on long-term secular growth drivers including global 5G deployment, edge-of-network computing, and datacenter expansion opportunities. Mar Vista believes these structural growth catalysts are not fully reflected in the current valuation following the interest rate-driven selloff. The manager views the Q4 decline as a temporary setback caused by Federal Reserve policy expectations rather than company-specific issues. The position reflects confidence in American Tower's ability to capitalize on global telecommunications infrastructure trends, particularly as 5G deployment accelerates and edge computing demand grows.

Pitch Summary:
Amazon's profitability was the key highlight of the third quarter financial results, with AWS and International Retail achieving record operating margins, and North America Retail posting its second-best margin in five years. Even more impressive was the fourth quarter operating income forecast, projecting up to $20 billion, significantly exceeding the expected $16 billion and suggesting a record 11% margin. This exceptional performance was driven by economies of scale, logistics efficiencies, successful AI implementations, increasing ad revenue, and accelerated AWS growth. We keep our investment in Amazon due to several factors: AWS growth has further potential, Amazon Prime Video monetization is in its initial stages, and the company is expanding into promising sectors like Pharmacy and Logistics. Furthermore, with strengthening profitability and cash reserves exceeding $100 billion, the possibility of substantial capital returns increases. By continuing to innovate and invest in technologies like AI and cloud computing, Amazon is well-positioned to keep its competitive edge.

BSD Analysis:
Mar Vista presents a strong bull case for Amazon centered on exceptional profitability improvements and multiple growth drivers. The manager highlights record operating margins across AWS and International Retail, with North America Retail achieving its second-best margin in five years. The Q4 operating income forecast of up to $20 billion significantly exceeded expectations, suggesting an 11% margin milestone. Key profitability drivers include economies of scale, logistics efficiencies, AI implementations, and accelerating ad revenue growth. The investment thesis rests on multiple expansion opportunities: continued AWS growth potential, early-stage Prime Video monetization, and expansion into pharmacy and logistics sectors. With over $100 billion in cash reserves and strengthening profitability, Amazon is positioned for potential substantial capital returns. The manager views Amazon's continued innovation in AI and cloud computing as sustainable competitive advantages that justify maintaining the position.

Pitch Summary:
Investors cheered a solid fiscal year Q3 performance from Salesforce, with results driven by strength in subscription revenues, current remaining performance obligations (CRPO), and operating margin. Both the Sales and Service Clouds returned to double-digit growth, fueled by strong adoption of multi-cloud and vertical-specific solutions. These results highlight Salesforce's ability to address diverse customer needs and sustain growth across its core offerings. Management expressed significant excitement about Agentforce, an organically developed generative AI product that is garnering enthusiasm from both system integrator partners and customers alike. This innovation underscores Salesforce's commitment to delivering innovative solutions that enhance customer engagement and drive productivity. While Agentforce's contributions to subscription revenues and CRPO bookings are still immaterial for now, the growing pipeline provides a solid foundation for optimism around Salesforce's ability to productize and monetize its generative AI offerings.

BSD Analysis:
Mar Vista maintains a bullish stance on Salesforce based on strong Q3 fundamentals and promising AI innovation. The manager highlights the return to double-digit growth in both Sales and Service Clouds, driven by multi-cloud and vertical-specific solution adoption. Key financial metrics including subscription revenues, current remaining performance obligations (CRPO), and operating margins all showed strength. The pitch emphasizes management's excitement around Agentforce, Salesforce's organically developed generative AI product gaining traction with partners and customers. While Agentforce's revenue contribution remains immaterial currently, the growing pipeline suggests strong monetization potential. The manager views Salesforce's ability to address diverse customer needs while innovating in generative AI as a competitive advantage. The combination of core business acceleration and AI product development positions Salesforce for sustained growth and customer engagement enhancement.

Pitch Summary:
Broadcom reported a strong fiscal year Q4 2024, exceeding expectations and reinforcing its leadership in custom AI accelerator solutions. Investors reacted positively to the company's robust performance and outlook, particularly for its AI semiconductor-related revenues and its long-term growth potential. The outlook for continued demand for Broadcom's custom AI accelerator products surprised many who expected a slowdown ahead of its new product, which is set to ramp in the second half of fiscal year 2025. The announcement of a long-term service addressable market (SAM) of $60-to-$90 billion further highlighted Broadcom's significant growth runway and market opportunity in the custom AI accelerator market. Broadcom's software business continues to deliver stable results, with the VMware acquisition integration performing ahead of plan. The stability in software business, coupled with Broadcom's strong execution and promising outlook in high-growth areas like AI semiconductors, should position the company for continued shareholder value creation.

BSD Analysis:
Mar Vista presents a compelling bull case for Broadcom centered on the company's dominant position in custom AI accelerators and successful VMware integration. The manager highlights Broadcom's Q4 2024 outperformance and robust AI semiconductor revenue outlook, with management announcing a massive $60-90 billion long-term service addressable market opportunity. The pitch emphasizes the surprising strength in AI accelerator demand despite expectations of a slowdown, with new products ramping in H2 2025. The VMware acquisition integration is proceeding ahead of schedule, providing stable software revenue streams. The combination of AI semiconductor growth momentum and software business stability positions Broadcom for sustained shareholder value creation. The manager's confidence stems from Broadcom's execution track record and its strategic positioning in high-growth AI infrastructure markets.

Pitch Summary:
Vertex is a high-quality biotech company run by a strong management team that has made a promising acquisition and advanced its diabetes pipeline. The developments gave us confidence that Vertex's innovative approach and high-quality management team will continue to achieve positive clinical outcomes and strengthen its competitive advantage.

BSD Analysis:
Parnassus added Vertex Pharmaceuticals based on the company's strong execution in expanding beyond its core cystic fibrosis franchise into new therapeutic areas. The investment thesis highlights management's strategic vision and execution capabilities, particularly noting a promising acquisition and advancement of the diabetes pipeline as key catalysts. The fund emphasizes Vertex's innovative drug development approach and proven track record of achieving positive clinical outcomes, which creates significant competitive advantages in the biotech sector. The timing suggests confidence in the company's ability to diversify its revenue base while maintaining its leadership in rare disease treatments. Vertex's strong cash generation from its CF franchise provides financial flexibility to fund pipeline development and strategic acquisitions. The investment reflects the fund's focus on high-quality biotech companies with experienced management teams and clear competitive moats. This represents a growth play in specialty pharmaceuticals with significant barriers to entry and strong pricing power.

Pitch Summary:
KLA, a leader in semiconductor process control, benefits from inherently high switching costs, structurally higher demand for advanced semiconductors and increasingly complex semiconductor manufacturing. The company has a strong management team that is positioning it well for long-term growth. Concerns about weaker demand in China have impacted KLA's stock price recently, but we believe the secular growth in other regions could offset the risk in the longer term.

BSD Analysis:
Parnassus initiated a position in KLA Corporation, viewing the recent China-related weakness as a buying opportunity in a high-quality semiconductor equipment company. The investment thesis centers on KLA's dominant position in process control and metrology equipment, which benefits from inherently high customer switching costs due to the mission-critical nature of their products in chip manufacturing. The fund emphasizes the structural growth drivers including increasing demand for advanced semiconductors and the growing complexity of manufacturing processes, which should drive higher content per wafer. Management quality is highlighted as a key factor in the company's ability to capitalize on long-term secular trends. While acknowledging near-term China exposure risks, the fund believes diversified global demand and the secular growth trajectory in other regions will more than offset geographic headwinds. This represents a strategic play on the semiconductor capital equipment cycle with strong competitive positioning and long-term growth visibility.

Pitch Summary:
Workday is a category leader for enterprise cloud applications for finance and human resources. We believe Workday's product stickiness and key initiatives such as its partnership with other service providers position the company well for incremental growth over the next few years.

BSD Analysis:
Parnassus added Workday as a new position, recognizing the company's leadership position in the enterprise cloud applications market for HR and finance functions. The investment thesis emphasizes Workday's strong competitive moat through high product stickiness, which creates significant switching costs for enterprise customers once implemented. The fund highlights strategic partnerships as a key growth driver that should expand Workday's addressable market and enhance its value proposition to clients. The timing suggests confidence in the company's ability to capture incremental growth as enterprises continue their digital transformation initiatives. Workday's SaaS model provides predictable recurring revenue streams with strong margins, while its focus on mission-critical HR and finance applications creates defensive characteristics. The investment reflects the fund's opportunistic approach to gaining exposure to high-quality technology companies during periods of sector volatility, positioning for long-term growth in the enterprise software market.

Pitch Summary:
Eli Lilly, the global pharmaceutical company, has an excellent GLP-1 franchise and a strong track record of innovation, which position the company for long-term growth. A rare revenue miss and President-elect Trump's health secretary nomination sparked a sell-off, providing a window of opportunity to gain exposure to the drugmaker's attractive product suite and pipeline at an attractive valuation.

BSD Analysis:
Parnassus opportunistically initiated a position in Eli Lilly following a temporary sell-off triggered by a rare revenue miss and political uncertainty around healthcare policy. The fund's investment thesis is anchored on Lilly's dominant GLP-1 franchise, which includes blockbuster diabetes and obesity treatments that represent a massive addressable market with significant pricing power. The manager emphasizes Lilly's consistent innovation track record as a key differentiator in the competitive pharmaceutical landscape. The timing of the purchase appears tactical, with the fund capitalizing on short-term volatility to gain exposure at what they view as an attractive valuation relative to the company's long-term growth prospects. The investment reflects confidence in Lilly's pipeline strength and the secular growth potential of the GLP-1 market, despite near-term political and regulatory headwinds. This represents a quality growth play in a defensive healthcare sector with significant barriers to entry.

Pitch Summary:
Ferguson's highly efficient operations, extensive distribution networks and broad product offerings give the company clear leadership over smaller, local competitors. Ferguson's scale advantages are expected to increase as it consolidates the fragmented industry structure. Additionally, the structural tailwinds of aging infrastructure and housing shortages should support Ferguson's long-term organic growth. Led by a tenured management team with a strong track record, the company is well positioned going forward, we believe.

BSD Analysis:
Parnassus initiated a position in Ferguson based on the company's dominant competitive positioning in the fragmented plumbing and construction supply distribution market. The fund highlights Ferguson's operational efficiency and extensive distribution network as key competitive moats that provide clear advantages over smaller local competitors. The investment thesis centers on the company's ability to consolidate market share in a fragmented industry while benefiting from structural growth drivers including aging U.S. infrastructure and housing supply shortages. Management quality is emphasized as a key factor, with the fund noting the leadership team's tenure and proven track record. The timing appears opportunistic, as Ferguson's scale advantages are expected to compound as industry consolidation accelerates. This represents a classic quality growth play in an essential services sector with defensive characteristics and long-term secular tailwinds.

Pitch Summary:
We re-entered a position in biotechnology company Vertex after selling our position in the first quarter of 2024. The company has since made a promising acquisition of Alpine Immune Sciences therapeutics and advanced its diabetes pipeline. The developments increased our confidence that Vertex's innovative approach and high-quality management team will continue to achieve positive clinical outcomes and strengthen its competitive advantage.

BSD Analysis:
Parnassus re-initiated a position in Vertex Pharmaceuticals after previously exiting earlier in 2024, citing improved pipeline prospects and strategic acquisitions. The Alpine Immune Sciences acquisition enhances Vertex's immunology capabilities and expands therapeutic opportunities beyond cystic fibrosis. Significant progress in the diabetes pipeline provides potential for major market expansion into a large addressable market. The fund emphasizes confidence in management's execution capabilities and track record of successful drug development. Vertex's innovative approach to rare disease treatment has historically generated strong returns and competitive moats. The company benefits from high barriers to entry in specialized therapeutic areas and strong intellectual property protection. Pipeline diversification reduces dependence on cystic fibrosis franchise while leveraging core competencies in precision medicine.

Pitch Summary:
Exact Sciences, a cancer diagnostic company, is approaching profitability and should be able to continue to grow its top and bottom line due to its leadership in non-invasive colorectal cancer tests and entry into new markets like cancer recurrence monitoring.

BSD Analysis:
Parnassus added Exact Sciences as part of its healthcare sector repositioning, attracted by the company's leadership in non-invasive cancer diagnostics and approaching profitability inflection. The company dominates the colorectal cancer screening market with its Cologuard test, benefiting from superior patient compliance compared to invasive alternatives. Exact Sciences is expanding beyond colorectal screening into cancer recurrence monitoring, significantly expanding its addressable market. The fund sees strong revenue and margin growth potential as the company scales operations and leverages its diagnostic platform. Healthcare cost pressures favor non-invasive testing solutions that improve patient outcomes while reducing system costs. The company benefits from aging demographics and increased cancer screening awareness. Exact Sciences' technology platform provides opportunities for additional test development and market expansion.

Pitch Summary:
Atlassian's innovative software allows IT developers and other employees to seamlessly collaborate on complex projects. Applications in their suite, such as Jira, are entrenched and widely recognized as industry standards. We believe the company is poised to benefit from an AI product cycle, as its platform becomes more integral to organizational software development.

BSD Analysis:
Parnassus initiated a position in Atlassian, recognizing the company's dominant position in developer collaboration tools and project management software. Jira and other Atlassian products have achieved industry-standard status, creating significant switching costs and customer stickiness. The fund sees Atlassian as well-positioned to capitalize on the artificial intelligence product cycle, as AI development requires enhanced collaboration and project management capabilities. The company's platform becomes increasingly critical as organizations scale their software development operations. Atlassian benefits from secular trends toward digital transformation and remote work collaboration. The fund believes AI integration will drive increased usage and pricing power across the product suite. Strong network effects exist as more team members adopt the platform within organizations.

Pitch Summary:
DoorDash holds a dominant market share, supported by a vast network of delivery people and merchants. DoorDash has strong topline and margin growth prospects for the next few years, driven by increases in gross order value, improvements in its take rate from ad monetization and expansion into new verticals like grocery.

BSD Analysis:
Parnassus added DoorDash as a replacement for LVMH, attracted by the food delivery leader's dominant market position and network effects. The company's extensive delivery driver and merchant network creates significant competitive moats and barriers to entry. Strong growth prospects are supported by multiple revenue drivers including gross order value expansion, advertising monetization improvements, and geographic/vertical expansion into grocery and other categories. The fund sees DoorDash as having a cleaner growth trajectory compared to luxury goods companies facing China exposure. Margin expansion opportunities exist as the platform scales and optimizes operations. The company benefits from secular trends toward convenience and on-demand services. DoorDash's platform economics should improve as density increases in existing markets.